Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Kiromic BioPharma, Inc. (KRBP)

0.2701   -0.005 (-1.78%) 11-25 12:59
Open: 0.275 Pre. Close: 0.275
High: 0.275 Low: 0.26
Volume: 28,746 Market Cap: 5(M)

Technical analysis

as of: 2022-11-25 1:58:24 PM
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Target: Six months: 0.36     One year: 0.4
Support: Support1: 0.25    Support2: 0.21
Resistance: Resistance1: 0.31    Resistance2: 0.35
Pivot: 0.27
Moving Average: MA(5): 0.26     MA(20): 0.28
MA(100): 0.35     MA(250): 0.66
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 16.6     %D(3): 13.3
RSI: RSI(14): 43.7
52-week: High: 2.45  Low: 0.23
Average Vol(K): 3-Month: 697 (K)  10-Days: 39 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ KRBP ] has closed above bottom band by 33.6%. Bollinger Bands are 70.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.28 - 0.28 0.28 - 0.28
Low: 0.26 - 0.26 0.26 - 0.26
Close: 0.27 - 0.28 0.28 - 0.28

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Headline News

Tue, 08 Nov 2022
SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects - PR Newswire

Mon, 03 Oct 2022
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate - Business Wire

Thu, 29 Sep 2022
KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire

Thu, 22 Sep 2022
KRBP 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Deadline in Securities Class Action - GlobeNewswire

Sat, 03 Sep 2022
KRBP EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit filed against Kiromic BioPharma, Inc. - GlobeNewswire

Sat, 20 Aug 2022
KRBP CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Kiromic BioPharma, Inc. Shareholders of Securities Fraud Class Action Lawsuit - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 18 (M)
Shares Float 11 (M)
% Held by Insiders 14.9 (%)
% Held by Institutions 4.9 (%)
Shares Short 561 (K)
Shares Short P.Month 414 (K)

Stock Financials

EPS -2.19
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.01
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -82.9
Return on Equity (ttm) -202.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.82
Qtrly Earnings Growth 0
Operating Cash Flow -29 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -0.13
PEG Ratio 0
Price to Book value 13.5
Price to Sales 0
Price to Cash Flow -0.18

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.